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portation costs. This experience may improve accessibility to
graft manipulated products for pediatric programs without
an on-site stem cell processing laboratory.183
Use of Laboratory Data to Enhance Donor Experience and
Implement a New Collection Device for HPC, Apheresis
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Background: About 80% of unrelated, allogeneic donations
for bone marrow transplant are collected as HPC, Apheresis
from peripheral blood using the National Marrow Donor
Program mobilization protocol, BB-IND #6821-0297 for ﬁl-
grastim (Amgen, Thousand Oaks, CA). The aging COBE
Spectra (Terumo, Inc., Golden, CO) was widely used for de-
cades. This collection method pre-dated most predictive
CD34+ counting, and collection orders were written
requesting a run of 24 liters of whole blood. Over-collections
of CD34+cells are seen with this method (mean¼225.17%,
n¼247), often as high as 3X to 6X. Terumo introduced a
replacement apheresis collection device, the Optia, with
updated electronic controls and a different method of
mononuclear cells extraction. The COBE will no longer be
supported in the near future, forcing collection centers to
make a device change.
Problem Statement: The collection efﬁciency of the COBE
device and operators was learned through experience. The
relationship of the previous collection estimation using “li-
ters processed” as a measure for the new device was un-
known. A process to allow training and use on the Optia
device while assuring the patient’s CD34+ cell collection goal
was required.
Materials and Methods: An implementation plan used the
Optia according to manufacturer’s instructions, using only
ACDA as the anticoagulant (no heparin, no aspirin), after staff
training by the vendor. The cell therapy laboratory supported
the implementation by testing the apheresis product at 2
hours into the procedure in order to calculate the size of the
collected product.
Results:
Conclusion: Concurrent CD34+ cell counting facilitated
implementation of the Optia collection method to meet
the collection goals. Frequent over-collection was cor-
rected with yields collections closer to prescription targets
(with slight over collection), mean of 142%. Use of yieldAverage Range






14.655 L  4.848 L 5.596 L e 27.207 L
% to target 142.44 %  60.26 % 61.40 % - 335.17 %





Collection Volume 16.368 L  6.003 L 5.477 L e 24.000 L
% to target 149.08 %  49.46 % 56.88 % - 267.67 %
*Excluded two poorly mobilized outliers, each with a peripheral blood
CD34+ counts of <15x103/mL.information improved collection efﬁciencies from around
20% to 60% with device adjustment. A predictive equation
using pre-CD34+ donor counts was mathematically tested
with the 48 collections and found to be highly predictive.
The average inlet volume was reduced by >40% and the
use of ACDA as the sole anticoagulant further improved
safety for the donor.184
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Background: Collecting high quality cord blood units
(CBU) is important because the TNC and CD34+ cell dose
of a CBU correlates with transplant outcomes. There are 2
techniques for collecting CBU: while the placenta is still
in-utero by midwives/obstetricians or after placental de-
livery by trained personal (ex-utero). The MD Anderson
Cord Blood Bank uses a combination of the 2 (in+ex utero)
techniques whenever feasible. The aim of this analysis was
to compare the 3 techniques (in-utero, ex-utero, in+ex-
utero).
Methods: CBUs collected between 04/2005 and 7/2011
were retrospectively analyzed. If logistically feasible, an
in-utero collection followed immediately by ex-utero
collection was performed. The total volume, pre- and post-
processing TNC, viable CD34+ cells and microbial
contamination was evaluated in the 3 groups. Analysis of
variance methods was used to compare the 3 groups with
respect to pre- and post-processing TNC and total viable
CD34+ cells. Tukey’s honestly signiﬁcant difference method
was used for pair-wise comparisons of the 3 groups. Mi-
crobial contamination between the groups was compared
using chi square test.
Results: Total of 32,738 CBUs were collected and 23,968
units were processed. The pre-processing TNC was signiﬁ-
cantly higher in the in-utero vs. ex-utero collections. There
was also a signiﬁcantly higher pre-processing TNC in the
in+ex utero collection vs. the in-utero collection. Similar re-
sults were noted in the post-processing TNC. The median
viable CD34+ cells collected were 5.03, 4.26, and 4.93 (x 106)
respectively in the in-utero, ex-utero and in+ex utero groups,
respectively (P< 0.0001 for in-utero vs. ex-utero and ex-
utero vs. in+ex-utero groups). There was no statistically
signiﬁcant difference in the microbial contamination in the
in-utero vs. in+ex utero groups, however it was lower in the
ex-utero collection as compared to either the in-utero or
in+ex utero collections.
Conclusion: We conclude that in+ex utero collection of
umbilical CB for banking is safe and results in signiﬁcantly
higher TNCs than either technique alone.






P value P-value P-value
Volume (ml) N¼8,906 N¼6,305 N¼17,527 <0.0001 <0.0001 <0.0001
Median 64.0 54.0 77.1
(Range) (0.5-225.3) (0.2-289.0) (2.0-289.1)
Pre-Processing TNC (x107) N¼6,133 N¼3,514 N¼14,321 < 0.0001 < 0.0001 < 0.0001
Median 108.8 101.0 118.9
(Range) (15.3-1144.8) (13.7-829.5) (9-1359.1)
Post-Processing TNC (x107) N¼4,009 N¼2,124 N¼9,559 < 0.0001 < 0.0001 < 0.0001
Median 113.4 105.4 118.4
(Range) (13.4-602.0) (3.8-459.8) (28.9-679.7)
Post-processing CD34+ cells ( x106) N¼3,857 N¼2,009 N¼9,069 < 0.0001 0.7670 < 0.0001
Median 5.03 4.26 4.93
(Range) (0.36-57.64) (0-53.03) (0.03-63.36)






< 0.0001 0.8278 < 0.0001
Table
Correlation of MSKCC post-thaw results with NCBP pre-cryopreservation
CBU and segment evaluation
VCD34+ cells Specimen, Lab Specimen, Lab N R2 p
pre-cryo, NCBP segment, NCBP 68 0.85 <0.0001
segment, NCBP post-thaw, MSKCC 68 0.72 <0.0001
pre-cryo, NCBP post-thaw, MSKCC 68 0.70 <0.0001
CFU Specimen, Lab Specimen, Lab
pre-cryo, NCBP segment, NCBP 43 0.52 <0.001
segment, NCBP post-thaw, MSKCC 63 0.22 <0.001
pre-cryo, NCBP post-thaw, MSKCC 42 0.20 0.0017
v. viable CD34+ cells: N: number of CBU (not all CBU had pre-cryopreser-
vation CFU data).
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Hematopoietic Progenitor Cell (HPC) mobilization should
take into consideration efﬁcacy, predictability, convenience
and cost. Despite many different schemas available, the
optimal growth factor regimen for chemo-mobilization is
still debatable. The standard growth factor used in HPC
mobilization is ﬁlgrastim (G-CSF) 10mcg/kg/day, adminis-
tered subcutaneously. Patients usually receive daily G-CSF
injections after chemotherapy in average of 10 days before
starting apheresis. Medicare patients have to go to hospital
or clinic every day to have their G-CSF injections given. We
retrospectively evaluated our experience with pegylated-
ﬁlgrastim given in conjunction with a subsequent short
course G-CSF in 15 patients (8F/7M) with multiple myeloma
(n¼6) and lymphoma (n¼9) who underwent chemo-growth
factor HPC mobilization for high-dose chemotherapy and
autologous stem cell transplantation. Median age was 68
(52-78). Chemotherapy regimen used for mobilizationwas at
the discretion of the transplant physician and included
cyclophosphamide (n¼2), DV-PACE (n¼5), DHAP (n¼2),
ESHAP (n¼2), EPOCH (n¼2), ICE (n¼1), mostly combined
with Rituximab. We planned ahead of time that chemo-
therapy is completed by the end of the week so that the
patient could spend the weekend at home and receive peg-
ﬁlgrastim at a single ﬁxed dose (6 mg) subcutaneously in the
following week with a median 3 (2-4) days after the last day
of chemotherapy. At the time of recovery when median WBC
was 0.6/mcL (0.1-3.8), daily G-CSF, at a median dose of 6mcg/
kg/day (5-12) was initiated in 5 (4-7) days after the dose of
pegﬁlgrastim. Five patients (33%) received additional Pler-
ixafor. HPC collection was started based on peripheral CD34
count in a median 3 days (1-6) after the initiation of G-CSF
and in 16 days (11-18) after the initial chemotherapy
administration. After 2 days (1-3) of apheresis, all patients
but one had adequate (>2 x 106) CD34+ cells/kg in HPC
product. Median CD34+ cell count on peripheral blood on
day+1 apheresis was 32 (4.6-407) x 106/kg. All patients had
full myeloid recovery and median time to ANC>500 x 3
consecutive days was 11 days (10-18) days. No graft failurewas observed. All patients tolerated the mobilization
regimen well with no serious side effects. Our preliminary
data suggest that single dose pegﬁlgrastim in conjunction
with low dose short course G-CSF can provide satisfactory
HPC mobilization and be considered an alternative conve-
nient growth factor regimen for select patients. A prospec-
tive study is currently underway in our institution.186
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Background: MSKCC analyses have shown that the infused
viable CD34+ cell dose is the critical determinant of neutro-
phil engraftment after CB transplantation (Purtill et al, Blood
2014). However, currently, CD34+ cell viability can only be
obtained on transplant day at unit thaw. Whether testing of
the segment attached to the freezing bag at the Bank prior to
unit release can predict the post-thaw CBU quality/potency
at the transplant center is not established.
Methods: We compared the post-thaw results of 68 NCBP
CBU, AXP-processed, stored in BioArchive freezers, shipped,
and thawed at MSKCC, with their respective segment and
